Literature DB >> 15310683

Revascularisation in diabetics with multivessel coronary artery disease.

K J Beatt1, K P Morgan, A Kapur.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15310683      PMCID： PMC1768460          DOI： 10.1136/hrt.2003.028852

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  17 in total

1.  Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.

Authors:  N S Kleiman; A M Lincoff; D J Kereiakes; D P Miller; F V Aguirre; K M Anderson; H F Weisman; R M Califf; E J Topol
Journal:  Circulation       Date:  1998-05-19       Impact factor: 29.690

2.  Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

Authors:  D L Bhatt; S P Marso; A M Lincoff; K E Wolski; S G Ellis; E J Topol
Journal:  J Am Coll Cardiol       Date:  2000-03-15       Impact factor: 24.094

3.  Argentine randomized trial of percutaneous transluminal coronary angioplasty versus coronary artery bypass surgery in multivessel disease (ERACI): in-hospital results and 1-year follow-up. ERACI Group.

Authors:  A Rodriguez; F Boullon; N Perez-Baliño; C Paviotti; M I Liprandi; I F Palacios
Journal:  J Am Coll Cardiol       Date:  1993-10       Impact factor: 24.094

4.  Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease.

Authors:  P W Serruys; F Unger; J E Sousa; A Jatene; H J Bonnier; J P Schönberger; N Buller; R Bonser; M J van den Brand; L A van Herwerden; M A Morel; B A van Hout
Journal:  N Engl J Med       Date:  2001-04-12       Impact factor: 91.245

5.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.

Authors:  W W O'Neill; P Serruys; M Knudtson; G A van Es; G C Timmis; C van der Zwaan; J Kleiman; J Gong; E B Roecker; R Dreiling; J Alexander; R Anders
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

7.  Five-year outcome after coronary angioplasty versus bypass surgery in multivessel coronary artery disease: results from the French Monocentric Study.

Authors:  D Carrié; M Elbaz; J Puel; J Fourcade; E Karouny; G Fournial; M Galinier
Journal:  Circulation       Date:  1997-11-04       Impact factor: 29.690

8.  Coronary angioplasty versus coronary artery bypass surgery: the Randomized Intervention Treatment of Angina (RITA) trial.

Authors: 
Journal:  Lancet       Date:  1993-03-06       Impact factor: 79.321

9.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Authors:  Marie-Claude Morice; Patrick W Serruys; J Eduardo Sousa; Jean Fajadet; Ernesto Ban Hayashi; Marco Perin; Antonio Colombo; G Schuler; Paul Barragan; Giulio Guagliumi; Ferenc Molnàr; Robert Falotico
Journal:  N Engl J Med       Date:  2002-06-06       Impact factor: 91.245

10.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

Authors:  Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.